JP7583728B2 - 重水素化ドンペリドンを含む製剤 - Google Patents

重水素化ドンペリドンを含む製剤 Download PDF

Info

Publication number
JP7583728B2
JP7583728B2 JP2021547550A JP2021547550A JP7583728B2 JP 7583728 B2 JP7583728 B2 JP 7583728B2 JP 2021547550 A JP2021547550 A JP 2021547550A JP 2021547550 A JP2021547550 A JP 2021547550A JP 7583728 B2 JP7583728 B2 JP 7583728B2
Authority
JP
Japan
Prior art keywords
formulation
weight
pharmaceutical formulation
domperidone
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021547550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512041A (ja
Inventor
パテル、ピユシュ
ピアース、キャサリン
イサクソン、ジョナサン
Original Assignee
シンドーム ファーマ、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンドーム ファーマ、インク． filed Critical シンドーム ファーマ、インク．
Publication of JP2022512041A publication Critical patent/JP2022512041A/ja
Priority to JP2022196699A priority Critical patent/JP7652751B2/ja
Application granted granted Critical
Publication of JP7583728B2 publication Critical patent/JP7583728B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021547550A 2018-10-25 2019-10-25 重水素化ドンペリドンを含む製剤 Active JP7583728B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022196699A JP7652751B2 (ja) 2018-10-25 2022-12-09 重水素化ドンペリドンを含む製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862750491P 2018-10-25 2018-10-25
US62/750,491 2018-10-25
PCT/US2019/058033 WO2020086947A1 (en) 2018-10-25 2019-10-25 Formulations containing deuterated domperidone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022196699A Division JP7652751B2 (ja) 2018-10-25 2022-12-09 重水素化ドンペリドンを含む製剤

Publications (2)

Publication Number Publication Date
JP2022512041A JP2022512041A (ja) 2022-02-01
JP7583728B2 true JP7583728B2 (ja) 2024-11-14

Family

ID=68582416

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547550A Active JP7583728B2 (ja) 2018-10-25 2019-10-25 重水素化ドンペリドンを含む製剤
JP2022196699A Active JP7652751B2 (ja) 2018-10-25 2022-12-09 重水素化ドンペリドンを含む製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022196699A Active JP7652751B2 (ja) 2018-10-25 2022-12-09 重水素化ドンペリドンを含む製剤

Country Status (12)

Country Link
US (2) US12514852B2 (https=)
EP (1) EP3668510B1 (https=)
JP (2) JP7583728B2 (https=)
KR (3) KR20240068762A (https=)
CN (1) CN113164463B (https=)
AU (1) AU2019366993B2 (https=)
CA (1) CA3117682A1 (https=)
ES (1) ES2852623T3 (https=)
IL (1) IL282575B (https=)
SG (1) SG11202103284QA (https=)
WO (1) WO2020086947A1 (https=)
ZA (1) ZA202102115B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136617A1 (en) * 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders
KR20240068762A (ko) 2018-10-25 2024-05-17 신돔 파마, 인크. 중수소화 돔페리돈을 함유하는 제제
EP4525868A1 (en) * 2022-04-20 2025-03-26 CinDome Pharma, Inc. Deuterated domperidone for treating gastroparesis
CN120813355A (zh) * 2023-03-23 2025-10-17 辛多美制药有限公司 用于治疗糖尿病性胃轻瘫的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136617A1 (en) 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702392D0 (en) 1997-02-06 1997-03-26 Boots Co Plc Therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20050220825A1 (en) 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
CN1686128A (zh) * 2005-04-19 2005-10-26 北京正大绿洲医药科技有限公司 多潘立酮滴丸及其制备方法
AU2008245580A1 (en) 2007-04-26 2008-11-06 Craig A. Aronchick Compositions and methods for transmucosal delivery of domperidone
CN102125528A (zh) 2010-01-12 2011-07-20 上海中邦斯瑞生物药业技术有限公司 多潘立酮口崩片
DE102010015143A1 (de) * 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
US9034858B2 (en) * 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
KR20240068762A (ko) 2018-10-25 2024-05-17 신돔 파마, 인크. 중수소화 돔페리돈을 함유하는 제제
WO2020086950A1 (en) 2018-10-25 2020-04-30 Cindome Pharma, Inc. Formulations containing domperidone

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136617A1 (en) 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ａｃｔａ Ｐｈａｒｍａｃｅｕｔｉｃａ ６３ （２０１３）， ｐ．２４１－２５１
Ｂｉｏｍｅｄｉｃｉｎｅ ＆ Ｐｈａｒｍａｃｏｔｈｅｒａｐｙ １０３ （２０１８．０７）， ｐ．５９８－６１３
Ｓｕｓｔａｉｎａｂｌｅ Ｃｈｅｍｉｓｔｒｙ ａｎｄ Ｐｈａｒｍａｃｙ ６ （２０１７）， ｐ．３７－５６

Also Published As

Publication number Publication date
KR20210080495A (ko) 2021-06-30
JP7652751B2 (ja) 2025-03-27
US12514852B2 (en) 2026-01-06
CN113164463B (zh) 2022-09-20
KR102667995B1 (ko) 2024-05-23
KR20240068762A (ko) 2024-05-17
NZ774559A (en) 2025-02-28
IL282575B (en) 2022-05-01
EP3668510A1 (en) 2020-06-24
CN113164463A (zh) 2021-07-23
JP2022512041A (ja) 2022-02-01
EP3668510B1 (en) 2021-01-13
WO2020086947A1 (en) 2020-04-30
US20220110929A1 (en) 2022-04-14
AU2019366993B2 (en) 2024-02-15
ZA202102115B (en) 2023-10-25
ES2852623T3 (es) 2021-09-14
JP2023036663A (ja) 2023-03-14
IL282575A (en) 2021-06-30
CA3117682A1 (en) 2020-04-30
US20260083717A1 (en) 2026-03-26
SG11202103284QA (en) 2021-05-28
AU2019366993A1 (en) 2021-05-06
KR20230169456A (ko) 2023-12-15
BR112021007754A2 (pt) 2021-07-27

Similar Documents

Publication Publication Date Title
JP7652751B2 (ja) 重水素化ドンペリドンを含む製剤
TW201041597A (en) Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
KR20110102393A (ko) 벤다무스틴의 경구 투약 형태
WO2009129297A1 (en) Semi-solid oral pharmaceutical compositions
KR102706357B1 (ko) 제약 제제
AU2024202861A1 (en) Formulations containing domperidone
RU2796537C2 (ru) Составы, содержащие дейтерированный домперидон
CA2627544A1 (en) Formulations of quinolinones for the treatment of cancer
AU2023262166A1 (en) Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
HK40033044A (en) Formulations containing deuterated domperidone
HK40033044B (en) Formulations containing deuterated domperidone
BR112021007754B1 (pt) Formulações contendo domperidona deuterada e uso das mesmas
HK40033468B (en) Formulations containing domperidone
HK40033468A (en) Formulations containing domperidone
BR112021007755B1 (pt) Formulações contendo domperidona e uso das mesmas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210814

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221209

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230224

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230228

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230307

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230310

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240831

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241101

R150 Certificate of patent or registration of utility model

Ref document number: 7583728

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150